Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 199.56B P/E 6.97 EPS this Y 42.90% Ern Qtrly Grth -98.20%
Income -2.59B Forward P/E 11.51 EPS next Y 8.70% 50D Avg Chg -6.00%
Sales 55.17B PEG 0.59 EPS past 5Y -3.07% 200D Avg Chg -17.00%
Dividend 5.00% Price/Book 1.98 EPS next 5Y 18.60% 52W High Chg -36.00%
Recommedations 2.40 Quick Ratio 0.51 Shares Outstanding 5.67B 52W Low Chg -
Insider Own 0.05% ROA 0.94% Shares Float 5.66B Beta 0.62
Inst Own 67.52% ROE -2.74% Shares Shorted/Prior 74.84M/61.73M Price 35.35
Gross Margin 60.16% Profit Margin -4.70% Avg. Volume 26,886,577 Target Price 33.34
Oper. Margin 22.40% Earnings Date Oct 29 Volume 34,241,200 Change -0.73%
About Pfizer, Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Pfizer, Inc. News
09:41 AM Pfizer Inc. (PFE) Is Among the Best Dividend Leaders to Buy According to Wall Street Analysts
07:00 AM The three-year loss for Pfizer (NYSE:PFE) shareholders likely driven by its shrinking earnings
05:06 AM The Stock Market Is Historically Pricey: Here's How I'm Positioning My Portfolio for 2025
04:05 AM My Top 10 Stocks to Buy for 2025
12/20/24 Novo Nordisk Shares Plunge After New Obesity Shot Disappoints
12/20/24 U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
12/20/24 Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
12/20/24 Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals
12/20/24 Is Pfizer (PFE) a Cheap NYSE Stock to Invest in Now?
12/19/24 Why Pfizer (PFE) Dipped More Than Broader Market Today
12/19/24 Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts
12/19/24 Is Pfizer Stock A Buy After Rallying On Its 2025 Guidance?
12/19/24 Pfizer Could Soar to $36 Per Share, According to a Wall Street Analyst. Is It a Buy at Around $26?
12/19/24 Merck’s RSV antibody could soon paddle into the rough waters of a crowded market
12/18/24 Pfizer 2025 Guidance Signals Relief to Investors, UBS Says
12/18/24 Jim Cramer’s Take on Pfizer (PFE): Can CEO Dr. Bourla’s Bold Strategy Overcome Debt and Turn the Stock Around?
12/18/24 Merck's BLA for RSV Antibody Clesrovimab Gets FDA Acceptance
12/18/24 Pfizer Stock Up 5% as 2025 Guidance Meets Investor Expectations
12/18/24 Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy
12/18/24 Trending tickers: Pfizer, Micron, Nissan, Teva and National Grid
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Gottlieb Scott Director Director Dec 15 Buy 26.4670 3,000 79,401 9,000 12/19/23
McDermott Michael Executive Vice Presi.. Executive Vice President Feb 25 Option 22.89 14,178 324,534 93,099 02/28/23
DAMICO JENNIFER B. SVP & Controller SVP & Controller Feb 25 Option 22.89 11,150 255,224 27,893 02/28/23
SUSMAN SALLY Executive Vice Presi.. Executive Vice President Feb 25 Option 22.89 72,984 1,670,604 209,179 02/28/23
Hwang Angela President, Global Bi.. President, Global Biopharma Feb 25 Option 22.89 20,273 464,049 44,541 02/28/23
JOHNSON RADY A Executive Vice Presi.. Executive Vice President Feb 25 Option 22.89 33,654 770,340 116,473 02/28/23
Hwang Angela President, Global Bi.. President, Global Biopharmaceu Feb 22 Option 30.17 57,032 1,720,655 67,027 02/24/23
SUSMAN SALLY Executive Vice Presi.. Executive Vice President Feb 22 Option 30.17 76,043 2,294,217 195,493 02/24/23
SAHNI PAYAL Executive Vice Presi.. Executive Vice President Feb 22 Option 30.17 15,209 458,856 32,671 02/24/23
McDermott Michael Executive Vice Presi.. Executive Vice President Feb 22 Option 30.17 13,307 401,472 88,957 02/24/23
JOHNSON RADY A Executive Vice Presi.. Executive Vice President Feb 22 Option 30.17 31,558 952,105 106,556 02/24/23
DAMICO JENNIFER B. SVP & Controller SVP & Controller Feb 22 Option 30.17 10,456 315,458 21,584 02/24/23
LANKLER DOUGLAS M Executive Vice Presi.. Executive Vice President Dec 14 Option 26.53 101,658 2,696,987 180,461 12/16/22
BOURLA ALBERT Chairman & CEO Chairman & CEO Dec 15 Option 26.53 222,328 5,898,362 411,890 12/16/22
DAMICO JENNIFER B. SVP & Controller SVP & Controller May 13 Sell 50.5000 4,000 202,000 15,064 05/17/22
SAHNI PAYAL Executive Vice Presi.. Executive Vice President May 13 Sell 49.8400 1,408 70,175 17,372 05/16/22
Carapezzi William R JR Executive Vice Presi.. Executive Vice President May 12 Sell 50.0000 32,908 1,645,400 38,146 05/13/22
LANKLER DOUGLAS M Executive Vice Presi.. Executive Vice President May 12 Sell 49.4100 38,273 1,891,069 78,803 05/13/22
Dolsten Mikael President R&D President R&D May 11 Sell 49.34 63,902 3,152,925 333,342 05/12/22
SUSMAN SALLY Executive Vice Presi.. Executive Vice President Feb 26 Option 25.6 63,580 1,627,648 172,880 03/01/22
DAMELIO FRANK A Executive Vice Presi.. Executive Vice President Feb 26 Option 25.6 127,160 3,255,296 649,918 03/01/22
SUSMAN SALLY Executive Vice Presi.. Executive Vice President Feb 23 Option 27.34 76,895 2,102,309 166,470 02/25/22
SAHNI PAYAL Executive Vice Presi.. Executive Vice President Feb 23 Option 27.34 13,884 379,589 29,391 02/25/22
LANKLER DOUGLAS M Executive Vice Presi.. Executive Vice President Feb 23 Option 27.34 115,342 3,153,450 181,659 02/25/22
JOHNSON RADY A Executive Vice Presi.. Executive Vice President Feb 23 Option 27.34 35,457 969,394 91,301 02/25/22
Hwang Angela Group President Group President Feb 23 Option 27.34 21,359 583,955 21,359 02/25/22
DAMELIO FRANK A Executive Vice Presi.. Executive Vice President Feb 23 Option 27.34 153,789 4,204,591 636,977 02/25/22
DAMICO JENNIFER B. SVP & Controller SVP & Controller Feb 23 Option 27.34 11,748 321,190 21,668 02/25/22
Carapezzi William R JR Executive Vice Presi.. Executive Vice President Feb 23 Option 27.34 25,632 700,779 82,914 02/25/22
YOUNG JOHN D Group President Group President Nov 11 Sell 50.09 150,000 7,513,500 312,704 11/12/21